Evidence map›Paper›PMID 34712359›Full record

ArticleOncology letters2021

Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway.

Sophie Gad, Gwenaël Le Teuff, Baptiste Nguyen, Virginie Verkarre, Veronique Duchatelle, Vincent Molinie, Katia Posseme, Benjamin Grandon, Melanie Da Costa, Bastien Job and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 2 countries.

Sophie GadEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Gwenaël Le TeuffDepartment of Biostatistics and Epidemiology, Gustave Roussy Institute, CNRS, Paris-Saclay University, 94800 Villejuif, France.
Baptiste NguyenEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Virginie VerkarreDepartment of Pathology, Public Hospitals of Paris (AP-HP) Centre, Georges Pompidou European Hospital, Paris University, 75015 Paris, France.
Veronique DuchatelleDepartment of Pathology, Saint-Joseph Hospital, 75014 Paris, France.
Vincent MolinieDepartment of Pathology, Saint-Joseph Hospital, 75014 Paris, France.
Katia PossemeDepartment of Pathology, AP-HP, Bicêtre Hospital, Paris-Saclay University, 94270 Le Kremlin-Bicêtre, France.
Benjamin GrandonEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Melanie Da CostaEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Bastien JobBioinformatics Core Facility, Gustave Roussy Institute, CNRS, Paris-Saclay University, 94800 Villejuif, France.
Guillaume MeuriceBioinformatics Core Facility, Gustave Roussy Institute, CNRS, Paris-Saclay University, 94800 Villejuif, France.
Nathalie DroinGenomics Core Facility, Gustave Roussy Institute, CNRS, Paris-Saclay University, 94800 Villejuif, France.
Arnaud MejeanDepartment of Urology, PREDIR French National Cancer Institute (INCa), AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France.
Sophie CouveEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Flore RenaudEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Betty GardieEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Bin Tean TehProgram in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School, Singapore 169610, Republic of Singapore.
Stephane RichardEcole Pratique des Hautes Etudes (EPHE), Paris Sciences Lettres Research University, 75014 Paris, France.
Sophie FerlicotMixed Research Unit (UMR) 9019, Gustave Roussy Institute, French National Scientific Research Center (CNRS), Paris-Saclay University, 94800 Villejuif, France.
École Pratique des Hautes Études · FRInstitut Gustave Roussy · FRBicêtre Hospital · FRCentre National de la Recherche Scientifique · FRHôpital Paris Saint-Joseph · FRHôpital Européen Georges-Pompidou · FRNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Von Hippel-Lindau (VHL) disease is the main cause of inherited clear-cell renal cell carcinoma (ccRCC) and is caused by germline mutations in the

Indexed as

BAF180clear cell renal cell carcinomahypoxia inducible factor 1hypoxia inducible factor 2polybromo 1 somatic mutationvon Hippel-Lindau diseaseVon Hippel-Lindau germline mutation

Identifiers

PMID34712359
PMCPMC8548775
OpenAlexW3206318473

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.